Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
Read Article
TNR: Gout Journal Club
https://t.co/vWNEof3F6b https://t.co/EgfqfKU1lx
Dr. John Cush @RheumNow( View Tweet )
đ„ In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know.
Watch now: https://t.co/KQmkdziLF5
#Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00
Dr. John Cush @RheumNow( View Tweet )
Do we need Better Strategies to Prevent Osteoporotic Fractures?
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
Read Article
ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis
In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial https://t.co/ax0zwNcxYX
Dr. John Cush @RheumNow( View Tweet )
RheumIQ: Per the 2025 EULAR RA recommendations, if a csDMARD strategy fails, which drug class requires careful risk assessment before use? Test your knowledge this week at https://t.co/z8mLbcgE5D. https://t.co/r61gvyMHPS
Dr. John Cush @RheumNow( View Tweet )
2026 Guidelines for the Treatment of Axial Spondyloarthritis
New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/3V8bfDptDU
Dr. John Cush @RheumNow( View Tweet )
EULAR26: GLP-1 Agonist Use in the RISE Registry
At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatologyâs (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). https://t.co/EqgETKjN1v
Dr. John Cush @RheumNow( View Tweet )
Insights into Treating Lupus - A Rheum Survey
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq
Dr. John Cush @RheumNow( View Tweet )
RT @aurelierheumo
What is new in PsA?
Dennis McGonagle's take at #EULAR2026
-a strong year for discovery in mechanisms of transition from PSO to PsA
-publication of the first single cell atlas Enthesis
-Better understanding of VTE mechanisms in JAKi in PsA
-clinical aspects
Dr. John Cush @RheumNow( View Tweet )
RT @jiharheum
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and â transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. #EULAR2026 OP0206
Dr. John Cush @RheumNow( View Tweet )
EULAR26: ANCHOR-RA Study of RA-ILD
EurekAlert!
People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality. ANCHOR-RA is a large, international cross-sectional prospective study that will enable the development of a multivariable model to help detect RA-ILD.5
Read Article
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management
EULAR has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous https://t.co/6WAZB1dOpI
Dr. John Cush @RheumNow( View Tweet )
EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA
EurekAlert!
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.
Read Article
EULAR26: Reports on Systemic Sclerosis
https://t.co/knZZlMYlen https://t.co/0wul0yaw4m
Dr. John Cush @RheumNow( View Tweet )
EULAR26: GLP-1 Agonist Use in the RISE Registry
EurekAlert!
At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatologyâs (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD).
Read Article
Spotlight on Comorbidities from EULAR 2026
EurekAlert!
Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality â possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the
Read Article
2026 Guidelines for the Treatment of Axial Spondyloarthritis
New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush @RheumNow( View Tweet )
EULAR26: Pitfalls in T2T
EULAR recommends T2T strategy in the management of RA and other RMD aiming for clinical remission or low disease activity guided by frequent monitoring and prompt therapy adjustments. But real-world daily implementation in remains poorly investigated. https://t.co/V6mCcdmyJz
Dr. John Cush @RheumNow( View Tweet )
EULAR26: Reports on Systemic Sclerosis
EurekAlert!
In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression â and time to these events â stratified by having a modified disease activity index (
Read Article
Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd
Dr. John Cush @RheumNow( View Tweet )
Brenda McShan: The Creative Heart of RheumNow
A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.
Brenda has been RheumNow's graphic artist since we began in 2014. She has well-earned her retirement, and leaves behind a decade of great work, dedication and exceptional graphics. RheumNow's
Read Article
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
Read Article
EULAR26: Updates in SLE and APS
EurekAlert!
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
Read Article
2026 Guidelines for the Treatment of Axial Spondyloarthritis
ACR
New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults,
Read ArticleTherapeutic Updates
Underserved and Under-treated
RheumNow
Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Pain Management and Workforce & APPs
Read Post
Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.
Read Post
Recent Blogs
At first, it seemed similar to many other such sessions â a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance â but this was special. I started the meetingâŠ. âHi, my name is Artie.â
Read Post
Podcasts
Day 4 Recap EULAR 2026
ACR 2025 Daily Podcasts Day4b-
ACR 2025 Daily Podcasts Day4a
